Overview

Benda Pharmaceutical, Inc., a China-based pharmaceutical company, is a pure play on explosive Chinese pharmaceutical spending and the global search for a cancer cure. Benda produces conventional and Traditional Chinese Medicines, as well as Genedicine®, the world's first commercialized gene therapy medicine for the treatment of cancer.

Investment Highlights

Market Potential

• The Chinese currently spend about $12 per capita on pharmaceuticals, as compared to $340 per capita in the U.S. As the Chinese population ages and become wealthier, the already large Chinese pharmaceutical market is poised for continued explosive growth.
• According to a recent report by McKinsey, Chinese healthcare spending will grow from $32 billion in 2004 to approximately $323 billion by 2025, or at a compound annual growth rate of 11.6%.
• By 2010, the Chinese pharmaceutical market will be the 5th largest in the world.

Subsidiaries

• Ribose (approximately $3.4 million) -- a core chemical previously produced at sister subsidiary Yidu Benda; and
• Ribavirin (approximately $5.7 million) -- an active pharmaceutical ingredient used to produce anti-virus medicines.

Financial Forecast

Recent News and Press Releases

Record $3.8 M in Gendicine(R) Orders in One Day Sells Out All Available Product; Promising Reported Results Drive Unprecedented Demand (Mon, Sep 24)

Benda Takes Major Step Toward Qualification for NASDAQ Listing by Establishing Independent Board (Fri, Sep 21)

Benda Unveils Dramatically Enhanced Gendicine(R) Distribution System, Provides Update on Number of Patients Treated to Date (Tue, Sep 18)

BENDA PHARMACEUTICAL, INC. Financials (Fri, Aug 31)

Benda Presenting to Thousands of Investors at the Washington D.C. Money Show (Fri, Aug 31)

Benda Subsidiary Benda Ebei Appoints New General Manager (Wed Aug, 29)

Benda Pharmaceutical Second Quarter 2007 Financial Results Call scheduled for 9:00 am ET today (Wed Aug 29)

Benda Pharmaceutical to Host Conference Call on August 29, 2007 to Review Second Quarter 2007 Financial Results (Tue Aug 28)

Benda Pharmaceutical Revenue Up 31% to $5.2 Million for the Quarter Ended June 30, 2007 (Mon, Aug 20)

BENDA PHARMACEUTICAL, INC. Files SEC form 10QSB, Quarterly Report (Mon, Aug 20)

Benda Subsidiary Jiangling Benda Resumes Production (Wed, Aug 15)

Benda CFO Featured in Exclusive WallSt.net Interview (Tue, Jul 24)

Benda Launches Comprehensive Online Investor Resource (Fri, Jun 29)

Benda Provides 2008 Financial Guidance (Tue, Jun 19)

Benda Increases Ownership in SiBiono, Producers of Gendicine(R) (Mon, Jun 18)

Benda Provides 2007 Financial Guidance and Operational Outlook (Wed, May 30)

Benda Pharmaceutical, Inc. to Host Conference Call on May 30, 2007 to Review First Quarter 2007 Financial Results (Thu, May 24)

Benda Pharmacuetical, Inc. Reports First Quarter Revenue of $3.0 Million (Mon, May 21)

BENDA PHARMACEUTICAL, INC. Financials (Thu, May 10)

Benda Pharmaceutical, Inc. Reports Record Annual Revenue of $15.9 Million (Fri, May 4)

BENDA PHARMACEUTICAL, INC. Financials (Tue, Apr 24)

Benda Acquires Majority Ownership of Shenzhen SiBiono GeneTech Co., Ltd. (Mon, Apr 9)

Management

Mr. Yiqing Wan, Chairman & CEO
• Co-Founder
• 20 years experience in pharmaceutical marketing and production
• Master’s Degree in Chemical Synthesis from Wuhan Chemical University; Bachelor’s Degree
in Biological Engineering from Sanxia University

Mr. Eric Yu, Director & CFO
• 13 years experience in public and corporate accounting and finance
• CPA, Hong Kong & Australia
• Bachelor of Commerce degree in Accountancy and Legal Studies from University of Wollongong,
Australia

Ms. Wei Xu, VP of Operations
• Co-Founder
• 25 years experience in pharmaceutical marketing
• EMBA from Peking University; Bachelor’s Degree in General Medicines from Wuhan Tongji
Medical University

Mr. Dr. Zhaohui Peng, Chairman of SiBiono
• Founder of SiBiono
• 15+ year devoted to gene therapy research, development, industrialization and commercialization
• PhD in Biological Chemistry from Japan’s Chiba University; postdoctorate at UCLA in
Biological Chemistry
 

Contacts

Company Contact:

Eric Yu, CFO
Email: Eric.Yu@bendapharma.com
Website: www.bendapharma.com

Investor Contact:

After Market Support, LLC
Justin Davis
Denver, Colorado
+1 (720) 489-4913
Email: Justin.Davis@AfterMarketSupport.com

FORWARD LOOKING STATEMENTS

This report includes forward-looking statements that reflect Benda Pharmaceutical, Inc. current expectations about its future results, performance, prospects and opportunities. Benda Pharmaceutical, Inc. has tried to identify these forward-looking statements by using words and phrases such as "may," "will," "expects," "anticipates," "believes," "intends," "estimates," "plan," "should," "typical," "preliminary," "we are confident" or similar expressions. These forward-looking statements are based on information currently available and are subject to a number of risks, uncertainties and other factors that could cause Benda Pharmaceutical, Inc.'s actual results, performance, prospects or opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. These risks, uncertainties and other factors include, without limitation, the Company's growth expectations and ongoing funding requirements, and specifically, the Company's growth prospects with scalable customers, and those outlined above. Other risks include the Company's limited operating history, the Company's history of operating losses, consumers' acceptance, the Company's use of licensed technologies, risk of increased competition, the potential need for additional financing, the terms and conditions of any financing that is consummated, the limited trading market for the Company's securities, the possible volatility of the Company's stock price, the concentration of ownership, and the potential fluctuation in the Company's operating results.

Disclaimer

AllPennyStocks.com feature stock reports are intended to be stock ideas, NOT recommendations. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this report was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. For more information see our disclaimer section, a link of which can be found on our web site. This document contains forward-looking statements, particularly as related to the business plans of the Company, within the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Actual results may differ materially from the Company's expectations and estimates. This is an advertisement for Benda Pharmaceutical, Inc. The purpose of this advertisement, like any advertising, is to provide coverage and awareness for the company. The information provided in this advertisement is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country.

© 1999-2007 AllPennyStocks.com. All rights reserved. AllPennyStocks.com is not a Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All materials presented on our web site and individual reports released to the public through this web site, e-mail or any other means of transmission are not to be regarded as investment advice and are only for informative purposes. Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with any stock, companies we select to profile involve a degree of investment risk and volatility. Particularly Small-Caps and OTC-BB stocks. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies. Past performance of our profiled stocks is not indicative of future results. The accuracy or completeness of the information on our web site or within our reports is only as reliable as the sources they were obtained from. The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. AllPennyStocks.com may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our web site or within our reports. In order to be in full compliance with the Securities Act of 1933, Section 17(b), AllPennyStocks.com will disclose in it's disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the AllPennyStocks.com web site. AllPennyStocks.com has been compensated seventeen thousand seven hundred and fifty dollars by the company for its efforts in presenting the BPMA profile on its web site and distributing it to its database of subscribers as well as other services. AllPennyStocks.com may decide to purchase or sell shares on a voluntary basis in the open market before, during or after the profiling period of this report. As of the profile date, no shares have been sold. Information presented on our web site and within our reports contain "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as “expects’”, “will,” “anticipates,” “estimates, “believes,” or that by statements indicating certain actions “may,” “could,” or “might” occur.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at: http://www.sec.gov and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.